Histology-proven recurrence in the lateral or central neck after systematic neck dissection for medullary thyroid cancer

Histology-proven recurrence in the lateral or central neck after systematic neck dissection for... Purpose To delineate risk factors for, and examine temporal patterns of, histology-proven recurrent medullary thyroid cancer (MTC) after compartment-oriented surgery. Methods Multivariate Cox regression on overall, node, and soft tissue infiltrate recurrence per previously dissected neck compartment. Results Mean follow-up for the 203 (and 158) patients with central (and ipsilateral lateral) neck dissection was 56.1 months. On multivariate Cox regression, tumor size > 20 mm predicted overall and node recurrence in the central neck, whereas extranodal growth predicted overall and node recurrence in the ipsilateral lateral neck. Extrathyroidal extension alone predicted soft tissue infiltrate recurrence in the central neck, and extranodal growth alone soft tissue infiltrate recurrence in the ipsilateral lateral neck. When analyses were restricted to patients not biochemically cured after initial surgery, only extranodal growth predicted overall and node recurrence in the dissected neck compartments. Conclusions Patients not biochemically cured, specifically those with extranodal growth at the initial operation, carry greater risks of node recurrence. ● ● ● Keywords Medullary thyroid carcinoma Lymph node metastasis Compartment-oriented neck dissection Node recurrence Soft tissue infiltrate recurrence Introduction ipsilateral lateral neck, whereas involvement of the con- tralateral lateral neck or the upper anterior mediastinum is Medullary thyroid cancer (MTC), a http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Endocrine Springer Journals

Histology-proven recurrence in the lateral or central neck after systematic neck dissection for medullary thyroid cancer

12 pages
Read Article

Loading next page...
 
/lp/springer_journal/histology-proven-recurrence-in-the-lateral-or-central-neck-after-vkO3RuXYdJ
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer Science+Business Media, LLC, part of Springer Nature
Subject
Medicine & Public Health; Endocrinology; Diabetes; Internal Medicine; Science, Humanities and Social Sciences, multidisciplinary
ISSN
1355-008X
eISSN
1559-0100
D.O.I.
10.1007/s12020-018-1625-1
Publisher site
See Article on Publisher Site

Abstract

Purpose To delineate risk factors for, and examine temporal patterns of, histology-proven recurrent medullary thyroid cancer (MTC) after compartment-oriented surgery. Methods Multivariate Cox regression on overall, node, and soft tissue infiltrate recurrence per previously dissected neck compartment. Results Mean follow-up for the 203 (and 158) patients with central (and ipsilateral lateral) neck dissection was 56.1 months. On multivariate Cox regression, tumor size > 20 mm predicted overall and node recurrence in the central neck, whereas extranodal growth predicted overall and node recurrence in the ipsilateral lateral neck. Extrathyroidal extension alone predicted soft tissue infiltrate recurrence in the central neck, and extranodal growth alone soft tissue infiltrate recurrence in the ipsilateral lateral neck. When analyses were restricted to patients not biochemically cured after initial surgery, only extranodal growth predicted overall and node recurrence in the dissected neck compartments. Conclusions Patients not biochemically cured, specifically those with extranodal growth at the initial operation, carry greater risks of node recurrence. ● ● ● Keywords Medullary thyroid carcinoma Lymph node metastasis Compartment-oriented neck dissection Node recurrence Soft tissue infiltrate recurrence Introduction ipsilateral lateral neck, whereas involvement of the con- tralateral lateral neck or the upper anterior mediastinum is Medullary thyroid cancer (MTC), a

Journal

Endocrine – Springer Journals

Published: Jun 5, 2018

References

  • Medullary carcinoma of the thyroid gland
    Chong, GC; Beahrs, OH; Sizemore, GW; Woolner, LH
  • Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma
    Tisell, LE; Hansson, G; Jansson, S; Salander, H
  • Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma
    Dralle, H; Damm, I; Scheumann, GFW; Kotzerke, J; Kupsch, E; Geerlings, H; Pichlmayr, R
  • Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection
    Moley, JF; DeBenedetti, MK
  • Biomarker-based risk stratification for previously untreated medullary thyroid cancer
    Machens, A; Dralle, H
  • Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level
    Machens, A; Schneyer, U; Holzhausen, HJ; Dralle, H
  • 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma
    Szakall, S; Esik, O; Bajzik, G; Repa, I; Dabasi, G; Sinkovics, I; Agoston, P; Tron, L
  • Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels
    Ong, SC; Schoder, H; Patel, SG; Tabangay-Lim, IM; Doddamane, I; Gonen, M; Shaha, AR; Tuttle, RM; Shah, JP; Larson, SM
  • 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels
    Hoegerle, S; Altehoefer, C; Ghanem, N; Brink, I; Moser, E; Nitzsche, E
  • Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma
    Verbeek, HH; Plukker, JT; Koopmans, KP; Groot, JW; Hofstra, RM; Muller Kobold, AC; Horst-Schrivers, AN; Brouwers, AH; Links, TP
  • The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT
    Beheshti, M; Pocher, S; Vali, R; Waldenberger, P; Broinger, G; Nader, M; Kohlfurst, S; Pirich, C; Dralle, H; Langsteger, W
  • Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma
    Luster, M; Karges, W; Zeich, K; Pauls, S; Verburg, FA; Dralle, H; Glatting, G; Buck, AK; Solbach, C; Neumaier, B; Reske, SN; Mottaghy, FM
  • Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer
    Kauhanen, S; Schalin-Jantti, C; Seppanen, M; Kajander, S; Virtanen, S; Schildt, J; Lisinen, I; Ahonen, A; Heiskanen, I; Vaisanen, M; Arola, J; Korsoff, P; Ebeling, T; Sane, T; Minn, H; Valimaki, MJ; Nuutila, P
  • Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma
    Treglia, G; Castaldi, P; Villani, MF; Perotti, G; Waure, C; Filice, A; Ambrosini, V; Cremonini, N; Santimaria, M; Versari, A; Fanti, S; Giordano, A; Rufini, V
  • There is more to life than death
    Hartzband, P; Groopman, J
  • Survival implications of cervical lymphadenectomy in patients with medullary thyroid cancer
    Kandil, E; Gilson, MM; Alabbas, HH; Tufaro, AP; Dackiw, A; Tufano, RP
  • Long-term results of reoperations and localization studies in patients with persistent or recurrent medullary thyroid cancer
    Kebebew, E; Shoichi, K; Duh, QY; Clark, O
  • Lymph node dissection and medullary thyroid carcinoma
    Dralle, H
  • AJCC Cancer Staging Manual
  • World Health Organization classification of tumours: Pathology and genetics of tumours of endocrine organs.
  • Multiple significance tests: the Bonferroni method
    Bland, JM; Altman, DG
  • Nonparametric estimation from incomplete observations
    Kaplan, EL; Meier, P
  • Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples
    Peto, R; Pike, MC; Armitage, P; Breslow, NE; Cox, DR; Howard, SV; Mantel, N; McPherson, K; Peto, J; Smith, PG
  • Regression models and life tables
    Cox, DR
  • Referral bias in thyroid cancer surgery: direction and magnitude
    Machens, A; Hauptmann, S; Dralle, H
  • Response to initial therapy predicts clinical outcomes in medullary thyroid cancer
    Lindsey, SC; Ganly, I; Palmer, F; Tuttle, RM
  • Integration of a postoperative calcitonin measurement into an anatomical staging system improves initial risk stratification in medullary thyroid cancer
    Yang, JH; Lindsey, SC; Camacho, CP; Valente, FO; Germano-Neto, F; Machado, AL; Mamone, MC; Brodskyn, F; Biscolla, RP; Tuttle, RM; Dias-da-Silva, MR; Maciel, RM
  • Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma
    Barbet, J; Campion, L; Kraeber-Bodéré, F; Chatal, JF
  • Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis
    Meijer, JA; Cessie, S; Hout, WB; Kievit, J; Schoones, JW; Romijn, JA; Smit, JW

You’re reading a free preview. Subscribe to read the entire article.

Try 2 weeks free now

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

or browse the journals available

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off

Sign up
for free
Start 14 day
Free Trial